The Enzen Trial: Comparison of Evar Endoprosthesis: Endurant Versus Zenith

The Enzen Trial: Comparison of EVAR Outcomes With Endurant Versus Zenith Endoprosthesis: a Prospective Analysis.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05969782

Acronym

ENZEN

Enrollment

100

Registered

2023-08-01

Start date

2023-07-01

Completion date

2024-09-01

Last updated

2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Aneurysm, Aortoiliac Atherosclerosis

Keywords

aneurysm, aortic, aortic disease

Brief summary

A prospective, non-randomized trial of patients submitted to EVAR for aortoiliac aneursym using Endurant II (Medtronic) or Zenith (Cook).

Detailed description

A prospective, non-randomized trial of patients submitted to EVAR for aortoiliac aneursym using Endurant II (Medtronic) or Zenith (Cook). The patients will be evaluated in a follow-up, regarding overall mortality rate, perioperative mortality rate and outcomes, such as Endoleaks and reinterventions.

Interventions

DEVICEEVAR

Endovascular repair of aortoiliac aneurysm using Zenith or Endurant

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

Aortoiliac infra-renal aneurysms. \-

Exclusion criteria

Thoracoabdominal aortic aneurysms, pararenal and supra-renal aortic aneurysms * Patients not suitable for EVAR.

Design outcomes

Primary

Measure	Time frame	Description
Perioperative Mortality rate	30 days	Mortality rate

Secondary

Measure	Time frame	Description
Reinterventions	2 years	Reinterventions during follow-up
Endoleaks	2 years	Endoleaks during follow-up

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026